Innovation Pharmaceuticals Inc (IPIX)

[Amatuer17]

AF is really stripping down Leo in that article. He has been proven right till now

“Knowing the baseline disease characteristics and prior/current treatment histories of the 12 enrolled patients is also necessary to interpret the Brilacidin data, but Cellceutix is withholding that information. Cellceutix CEO Leo Ehlrich did not provide the information when I asked for it.

nstead, Ehrlich likes to compare brilacidin favorably to anti-TNF biologics like Abbvie's Humira. In doing so, Ehrlich is assuming investors are dumb and don't know how UP/UPS or any form of ulcerative colitis is treated.